Nektar Q2 net loss $41.6M; rezpegaldesleukin Fast Track; cash runway into Q1 2027

NEKTAR THERAPEUTICS

2025-Q2 EPS reported -$6.57 revenue$21,635,000

Revenue $11.2M Q2 2025 vs $23.5M Q2 2024; decrease due to sale of Huntsville facility.
Net loss $41.6M ($2.95 per share) vs $52.4M loss ($3.76 per share) in Q2 2024.
Cash and investments $175.9M at June 30, 2025; excludes $107.5M net proceeds from July 2025 offering; runway into Q1 2027.
FDA Fast Track granted for rezpegaldesleukin in severe-to-very severe alopecia areata (July 2025).
REZOLVE-AD Phase 2b met primary and key secondary endpoints at week 16; 52-week data expected early 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.